Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Cytokinetics Inc (CYTK)  
$49.87 1.36 (2.8%) as of 4:30 Mon 6/3


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 122,563,000
Market Cap: 6.11(B)
Last Volume: 8,264,325 Avg Vol: 8,241,765
52 Week Range: $26.88 - $108.06
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 91,318 224,559 397,579 888,401
Total Sell Value $6,319,460 $16,400,468 $22,217,779 $44,103,545
Total People Sold 2 4 5 11
Total Sell Transactions 4 15 35 82
End Date 2024-03-03 2023-12-01 2023-06-02 2022-06-02

   
Records found: 1105
  Page 2 of 45  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-03-05 4 OE $6.67 $190,789 D/D 28,604 167,577     -
   Callos Andrew EVP, Chief Commercial Officer   •       •      –    2024-03-04 4 D $67.68 $149,031 D/D (2,202) 52,049     -
   Wong Robert VP, Chief Accounting Officer   •       •      –    2024-03-04 4 D $67.68 $120,673 D/D (1,783) 26,442     -
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-03-04 4 D $67.68 $651,758 D/D (9,630) 133,343     -
   Blum Robert I President & CEO   •       •      –    2024-03-04 4 D $67.68 $1,715,079 D/D (25,341) 416,456     -
   Henderson John T Director   •       •      –    2024-02-14 4 AS $76.48 $382,400 D/D (5,000) 42,632 -37%     
   Henderson John T Director   •       •      –    2024-02-14 4 OE $4.44 $22,200 D/D 5,000 47,632     -
   Blum Robert I President & CEO   •       •      –    2024-02-13 4 AS $76.85 $960,625 D/D (12,500) 441,797 -37%     
   Blum Robert I President & CEO   •       •      –    2024-02-13 4 OE $6.67 $83,375 D/D 12,500 454,297     -
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-02-06 4 AS $79.28 $2,585,497 D/D (32,605) 142,973 -39%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-02-06 4 OE $6.67 $190,795 D/D 28,605 175,578     -
   Blum Robert I President & CEO   •       •      –    2024-01-31 4 AS $79.57 $994,625 D/D (12,500) 441,797 -38%     
   Blum Robert I President & CEO   •       •      –    2024-01-31 4 OE $6.67 $83,375 D/D 12,500 454,297     -
   Blum Robert I President & CEO   •       •      –    2024-01-19 4 AS $81.42 $1,017,750 D/D (12,500) 441,797 -39%     
   Blum Robert I President & CEO   •       •      –    2024-01-19 4 OE $6.67 $83,375 D/D 12,500 454,297     -
   Henderson John T Director   •       •      –    2024-01-12 4 AS $85.14 $425,700 D/D (5,000) 42,632 -43%     
   Henderson John T Director   •       •      –    2024-01-12 4 OE $4.44 $22,200 D/D 5,000 47,632     -
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-01-04 4 AS $86.98 $1,363,712 D/D (15,678) 146,973 -31%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-01-04 4 OE $7.96 $92,957 D/D 11,678 162,651     -
   Kaye Edward M. Md Director   •       •      –    2024-01-02 4 A $84.12 $12,450 D/D 148 19,317     -
   Harrington Robert Arthur Director   •       •      –    2024-01-02 4 A $84.12 $12,450 D/D 148 11,521     -
   Henderson John T Director   •       •      –    2024-01-02 4 A $84.12 $21,198 D/D 252 42,632     -
   Smith Sandford D Director   •       •      –    2024-01-02 4 A $84.12 $12,450 D/D 148 18,801     -
   Wysenski Nancy Director   •       •      –    2024-01-02 4 A $84.12 $6,225 D/D 74 17,156     -
   Wierenga Wendall D Director   •       •      –    2024-01-02 4 A $84.12 $6,225 D/D 74 18,727     -
  1105 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 2 of 45
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us